JP2022511335A - 人工涙液組成物、コンタクトレンズ組成物及び薬剤ビヒクル組成物、並びにこれらの使用の方法 - Google Patents

人工涙液組成物、コンタクトレンズ組成物及び薬剤ビヒクル組成物、並びにこれらの使用の方法 Download PDF

Info

Publication number
JP2022511335A
JP2022511335A JP2021515543A JP2021515543A JP2022511335A JP 2022511335 A JP2022511335 A JP 2022511335A JP 2021515543 A JP2021515543 A JP 2021515543A JP 2021515543 A JP2021515543 A JP 2021515543A JP 2022511335 A JP2022511335 A JP 2022511335A
Authority
JP
Japan
Prior art keywords
composition
approximately
concentration
mmol
tear
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021515543A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020061249A5 (fr
Inventor
ホーン，ジェラルド
Original Assignee
ピー・エス・セラピー・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/137,738 external-priority patent/US20190021990A1/en
Priority claimed from US16/372,596 external-priority patent/US20190225917A1/en
Priority claimed from US16/372,582 external-priority patent/US20190224136A1/en
Priority claimed from US16/372,625 external-priority patent/US11583496B2/en
Priority claimed from US16/412,943 external-priority patent/US20190262290A1/en
Application filed by ピー・エス・セラピー・リミテッド filed Critical ピー・エス・セラピー・リミテッド
Publication of JP2022511335A publication Critical patent/JP2022511335A/ja
Publication of JPWO2020061249A5 publication Critical patent/JPWO2020061249A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2021515543A 2018-09-21 2019-09-19 人工涙液組成物、コンタクトレンズ組成物及び薬剤ビヒクル組成物、並びにこれらの使用の方法 Pending JP2022511335A (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US16/137,738 US20190021990A1 (en) 2016-10-12 2018-09-21 Artificial tear compositions and methods of use thereof
US16/137,738 2018-09-21
US16/372,625 2019-04-02
US16/372,582 2019-04-02
US16/372,596 US20190225917A1 (en) 2016-10-12 2019-04-02 Contact lens compositions and methods of use thereof
US16/372,582 US20190224136A1 (en) 2016-10-12 2019-04-02 Artificial tear compositions and methods of use thereof
US16/372,625 US11583496B2 (en) 2016-10-12 2019-04-02 Drug vehicle compositions and methods of use thereof
US16/372,596 2019-04-02
US16/412,943 US20190262290A1 (en) 2016-10-12 2019-05-15 Drug vehicle compositions and methods of use thereof
US16/412,943 2019-05-15
PCT/US2019/051825 WO2020061249A2 (fr) 2018-09-21 2019-09-19 Larmes artificielles, lentilles de contact et compositions de véhicule pour médicament et leurs procédés d'utilisation

Publications (2)

Publication Number Publication Date
JP2022511335A true JP2022511335A (ja) 2022-01-31
JPWO2020061249A5 JPWO2020061249A5 (fr) 2022-09-28

Family

ID=69887791

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021515543A Pending JP2022511335A (ja) 2018-09-21 2019-09-19 人工涙液組成物、コンタクトレンズ組成物及び薬剤ビヒクル組成物、並びにこれらの使用の方法

Country Status (6)

Country Link
EP (1) EP3853317A4 (fr)
JP (1) JP2022511335A (fr)
CN (1) CN113227304A (fr)
BR (1) BR112021005097A2 (fr)
CA (1) CA3112278A1 (fr)
WO (1) WO2020061249A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220350163A1 (en) * 2021-04-29 2022-11-03 Coopervision International Limited Ws12-releasing contact lens
CN115671256B (zh) * 2021-07-30 2024-04-09 四川大学华西医院 环孢素a与地夸磷索钠联合使用在制备治疗干眼症的药物中的用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2422031C (fr) * 2000-09-13 2011-11-15 Santen Pharmaceutical Co., Ltd. Solutions ophtalmiques comprenant difluoroprostaglandine f2 alpha
WO2009035034A1 (fr) * 2007-09-14 2009-03-19 Rohto Pharmaceutical Co., Ltd. Composition opthalmique
KR20120112537A (ko) * 2009-12-15 2012-10-11 포어사이트 바이오쎄라퓨틱스, 인코퍼레이티드 무자극성 안과용 포비돈-요오드 조성물
US8597629B1 (en) * 2013-06-21 2013-12-03 Premium Ocular Solutions LLC. Artificial tear compositions comprising a combination of nonionic surfactants
US20140377210A1 (en) * 2013-06-21 2014-12-25 Gnt, Llc Artificial tear compositions
WO2016123079A1 (fr) * 2015-01-26 2016-08-04 Bausch & Lomb Incorporated Composition de suspension ophtalmique
US20180161438A1 (en) * 2015-05-28 2018-06-14 Rohto Pharmaceutical Co., Ltd. Aqueous Ophthalmic Composition
EP3525885B1 (fr) * 2016-10-12 2022-01-26 PS Therapy Ltd. Larmes artificielles, lentilles de contact et compositions de véhicule pour médicament et leurs procédés d'utilisation

Also Published As

Publication number Publication date
EP3853317A2 (fr) 2021-07-28
BR112021005097A2 (pt) 2021-06-08
WO2020061249A2 (fr) 2020-03-26
CA3112278A1 (fr) 2020-03-26
EP3853317A4 (fr) 2022-06-22
CN113227304A (zh) 2021-08-06
WO2020061249A3 (fr) 2020-07-23

Similar Documents

Publication Publication Date Title
JP7432654B2 (ja) 人工涙液、コンタクトレンズ及び薬剤担体組成物並びにその使用方法
US11583496B2 (en) Drug vehicle compositions and methods of use thereof
US11260035B2 (en) Topical compositions and methods of use thereof
EP1972344A1 (fr) Formule ophtalmique pour la prévention et le traitement de conditions oculaires
ZA200503975B (en) Use of rimexolone in the treatment of dry eye
US20200009044A1 (en) Artificial tear, contact lens and drug vehicle compositions and methods of use thereof
JP2013534527A (ja) コンタクトレンズ乳頭結膜炎及びアレルギー性眼疾患の予防及び処置のための組成物
US20220080048A1 (en) Opthalmological compositions and methods of use thereof
JP2022511335A (ja) 人工涙液組成物、コンタクトレンズ組成物及び薬剤ビヒクル組成物、並びにこれらの使用の方法
TWI650122B (zh) 用於預防及／或治療乾眼症之組成物、方法及／或裝置
US20190262290A1 (en) Drug vehicle compositions and methods of use thereof
KR102268002B1 (ko) 효과 지속성 점안제 조성물
Kymionis et al. Dry eye after photorefractive keratectomy with adjuvant mitomycin C
US20190021990A1 (en) Artificial tear compositions and methods of use thereof
WO2021087051A1 (fr) Compositions topiques et leurs procédés d'utilisation
US20230285286A1 (en) Drug vehicle compositions and methods of use thereof
US20230235247A1 (en) Contact lens compositions and methods of use thereof
US20200397727A1 (en) Drug vehicle compositions and methods of use thereof
US20220133626A1 (en) Topical compositions and methods of use thereof
KR100938233B1 (ko) 프로스타글란딘계 점안용 조성물과 그의 제조 방법
US20190225917A1 (en) Contact lens compositions and methods of use thereof
US20190224136A1 (en) Artificial tear compositions and methods of use thereof
Akers et al. Practical Aspects of Ophthalmic Drug Devlopment
CA2567418C (fr) Epaississant a usage ophthalmique

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210520

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211202

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220916

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220916

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231031

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240521